OCA
Octagon Capital Advisors Portfolio holdings
AUM
$456M
This Quarter Return
+5.87%
1 Year Return
+48.55%
3 Year Return
+560.4%
5 Year Return
–
10 Year Return
–
AUM
$514M
AUM Growth
+$514M
(+27%)
Cap. Flow
+$147M
Cap. Flow
% of AUM
28.56%
Top 10 Holdings %
Top 10 Hldgs %
77.97%
Holding
36
New
6
Increased
8
Reduced
5
Closed
8
Top Buys
| 1 |
Arcus Biosciences
RCUS
|
$45.5M |
| 2 |
iTeos Therapeutics
ITOS
|
$21M |
| 3 |
Apellis Pharmaceuticals
APLS
|
$20.1M |
| 4 |
BridgeBio Pharma
BBIO
|
$20M |
| 5 |
Keros Therapeutics
KROS
|
$19.9M |
Top Sells
| 1 |
Curis
CRIS
|
$18M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$4.5M |
| 3 |
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
|
$4.2M |
| 4 |
IMA
ImageneBio, Inc. Common Stock
IMA
|
$3.47M |
| 5 |
PMV Pharmaceuticals
PMVP
|
$2.98M |
Sector Composition
| 1 | Healthcare | 99.43% |
| 2 | Financials | 0.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Apellis Pharmaceuticals
APLS
$3.48B
| $95.5M | 18.59% | 2,020,911 +425,000 | +27% | +$20.1M |
|
|
2
Arcus Biosciences
RCUS
$1.13B
| $84.8M | 16.5% | 2,095,231 +1,125,067 | +116% | +$45.5M |
|
|
IMAB
3
I-MAB
IMAB
$340M
| $49.7M | 9.68% | 1,049,691 +285,230 | +37% | +$13.5M |
|
4
4D Molecular Therapeutics
FDMT
$288M
| $34M | 6.62% | 1,551,070 +719,803 | +87% | +$15.8M |
|
|
5
BridgeBio Pharma
BBIO
$9.89B
| $29.5M | 5.74% | 1,767,486 +1,198,072 | +210% | +$20M |
|
6
Celldex Therapeutics
CLDX
$1.47B
| $29.4M | 5.73% | 761,398 | – | – |
|
|
7
iTeos Therapeutics
ITOS
$449M
| $21M | 4.08% | +450,776 | New | +$21M |
|
|
8
Keros Therapeutics
KROS
$618M
| $19.9M | 3.87% | +340,214 | New | +$19.9M |
|
9
Stoke Therapeutics
STOK
$1.08B
| $18.8M | 3.66% | 783,769 +486,947 | +164% | +$11.7M |
|
10
Vera Therapeutics
VERA
$1.38B
| $17.9M | 3.49% | 670,940 -25,186 | -4% | -$673K |
|
11
Gossamer Bio
GOSS
$562M
| $17.1M | 3.33% | 1,513,138 | – | – |
|
12
Arvinas
ARVN
$568M
| $14.7M | 2.85% | 178,500 +10,000 | +6% | +$821K |
|
13
Century Therapeutics
IPSC
$42.5M
| $11.1M | 2.17% | 702,623 +100,000 | +17% | +$1.59M |
|
14
Avidity Biosciences
RNA
$5.99B
| $10.6M | 2.07% | 446,641 | – | – |
|
|
KDNY
15
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $8.16M | 1.59% | +500,000 | New | +$8.16M |
|
|
RXDX
16
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $7.91M | 1.54% | 200,000 | – | – |
|
17
Dyne Therapeutics
DYN
$1.92B
| $6.94M | 1.35% | 583,649 | – | – |
|
18
Cytek Biosciences
CTKB
$527M
| $6.53M | 1.27% | 400,000 -100,000 | -20% | -$1.63M |
|
19
Cardiff Oncology
CRDF
$140M
| $5.91M | 1.15% | 982,753 | – | – |
|
20
Immunovant
IMVT
$2.56B
| $4.88M | 0.95% | +572,862 | New | +$4.88M |
|
21
MoonLake Immunotherapeutics
MLTX
$3.54B
| $3.96M | 0.77% | 400,000 | – | – |
|
22
Monte Rosa Therapeutics
GLUE
$296M
| $3.06M | 0.6% | 150,000 | – | – |
|
|
AMAM
23
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $3.04M | 0.59% | 336,868 -13,132 | -4% | -$119K |
|
|
JYAC
24
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
| $2.93M | 0.57% | 300,000 | – | – |
|
25
Olema Pharmaceuticals
OLMA
$375M
| $2.17M | 0.42% | +231,417 | New | +$2.17M |
|